The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis by Jiménez-Medina, Eva et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
The immunomodulator PSK induces in vitro cytotoxic activity in 
tumour cell lines via arrest of cell cycle and induction of apoptosis
Eva Jiménez-Medina1, Enrique Berruguilla1, Irene Romero1, Ignacio Algarra2, 
Antonia Collado3, Federico Garrido1 and Angel Garcia-Lora*1
Address: 1Servicio de Análisis Clínicos e Inmunologia, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Av. de las Fuerzas 
Armadas 2, 18014 Granada, Spain, 2Departamento de Ciencias de la Salud, Universidad Jaén, Jaén, Spain and 3Unidad de Investigación, Hospital 
Universitario Virgen de las Nieves, Granada, Spain
Email: Eva Jiménez-Medina - evajimenez@fundacionhvn.org; Enrique Berruguilla - quiquebp@hotmail.com; Irene Romero - iroga@ya.com; 
Ignacio Algarra - ialgarra@ujaen.es; Antonia Collado - antonia.collado.sspa@juntadeandalucia.es; 
Federico Garrido - federico.garrido.sspa@juntadeandalucia.es; Angel Garcia-Lora* - angel.miguel.exts@juntadeandalucia.es
* Corresponding author    
Abstract
Background: Protein-bound polysaccharide (PSK) is derived from the CM-101 strain of the
fungus Coriolus versicolor and has shown anticancer activity in vitro and in in vivo experimental models
and human cancers. Several randomized clinical trials have demonstrated that PSK has great
potential in adjuvant cancer therapy, with positive results in the adjuvant treatment of gastric,
esophageal, colorectal, breast and lung cancers. These studies have suggested the efficacy of PSK
as an immunomodulator of biological responses. The precise molecular mechanisms responsible
for its biological activity have yet to be fully elucidated.
Methods: The in vitro cytotoxic anti-tumour activity of PSK has been evaluated in various tumour
cell lines derived from leukaemias, melanomas, fibrosarcomas and cervix, lung, pancreas and gastric
cancers. Tumour cell proliferation in vitro was measured by BrdU incorporation and viable cell
count. Effect of PSK on human peripheral blood lymphocyte (PBL) proliferation in vitro was also
analyzed. Studies of cell cycle and apoptosis were performed in PSK-treated cells.
Results:  PSK showed in vitro inhibition of tumour cell proliferation as measured by BrdU
incorporation and viable cell count. The inhibition ranged from 22 to 84%. Inhibition mechanisms
were identified as cell cycle arrest, with cell accumulation in G0/G1 phase and increase in apoptosis
and caspase-3 expression. These results indicate that PSK has a direct cytotoxic activity in vitro,
inhibiting tumour cell proliferation. In contrast, PSK shows a synergistic effect with IL-2 that
increases PBL proliferation.
Conclusion: These results indicate that PSK has cytotoxic activity in vitro on tumour cell lines. This
new cytotoxic activity of PSK on tumour cells is independent of its previously described
immunomodulatory activity on NK cells.
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Background
A number of bioactive molecules, including antitumour
substances, have been identified in various mushroom
species. Polysaccharides are the best known and most
potent of these and have antitumour and immunomodu-
lating properties [1-5]. PSK, a protein-bound polysaccha-
ride obtained from Basidiomycetes, also known as Krestin,
has been used as an agent in the treatment of cancer in
Asia for over 30 yrs [6-8]. PSK is derived from the fungus
Coriolus versicolor and has documented anticancer activity
in vitro in experimental models [9] and in human clinical
trials. Several randomized clinical trials have demon-
strated that PSK has great potential in adjuvant cancer
therapy, with positive results in the treatment of gastric,
esophageal, colorectal, breast and lung cancers [10,11].
These studies have suggested the efficacy of PSK as an
immunomodulator of biological response.
Previous reports indicated that PSK might act in different
ways: as antioxidant [5,12,13]; as inhibitor of metallopro-
teinases and other enzymes involved in metastatic proc-
esses [14] and as inhibitor of the action of various
carcinogens in vulnerable cell lines. However its most
important and widely reported property is its immu-
nomodulatory capacity. PSK may act to increase leukocyte
activation and response via upregulation of key cytokines.
Thus, natural killer (NK) and lymphocyte-activated killer
(LAK) cell activation has been demonstrated in vivo and in
vitro [15,16]. Our group demonstrated that PSK is capable
of inhibiting metastatic colonization in vivo in some
experimental fibrosarcomas, and that this effect is medi-
ated by activation of NK cells [17,18]. Moreover, the NK
cell line NKL, derived from a large granular lymphocyte
leukaemia [19], is activated in vitro by PSK [16]. This acti-
vation may replace IL-2 in inducing the proliferation and
cytotoxicity of NKL cells. The signal transduction path-
ways involved in the responses to IL-2 or PSK are different:
IL-2 increases PKCα and ERK3 expression and decreases
ERK2 expression, whereas PSK decreases PKCα expression
and increases ERK3 expression [20]. PSK also enhances
CRE binding activity, while IL-2 increases SP-1 and modi-
fies GAS/ISRE, IRF-1 and STAT5 [21]. In addition, PSK and
IL-2 have been shown to bind to different receptor on
NKL cells [22].
The direct in vitro effect of PSK on the proliferation of
tumour cell lines was compared with its effect on PBLs.
PSK had cytotoxic activity on tumour cell lines, inhibiting
proliferation, producing cell cycle arrest and cell accumu-
lation in G0/G1phase and inducing apoptosis.
Methods
Protein-bound polysaccharide K
Protein-bound polysaccharide K (PSK) was kindly pro-
vided by Kureha Chemical Ind. Co. (Tokyo, Japan). It is
prepared by extracting cultured mycelia of Coriolus versi-
color with hot water. The precipitate is separated from the
clear supernatant with saturated ammonium sulfate, then
desalted and dried [23]. Protein-bound polysaccharide K
was dissolved in RPMI medium or water and heated at
50°C for 20–30 min until a clear solution appeared. The
PSK preparation was filter-sterilized and diluted in culture
medium or water to the desired concentration. Protein-
bound polysaccharide K was previously titrated in NKL
cells [16] and the working dilution was 100 μg/mL. PSK
extract digested with neuraminidase was also tested,
digesting 100 μg of PSK with 4 μl (Sigma) and incubating
for 3 h at 37°C. Our group previously showed that PSK is
composed of two bands of very high molecular weight
[22]. After digestion with neuraminidase, these bands are
reduced to a single band of about 12 kd. These results
indicate that PSK is probably composed of a single 12-kd
protein, and that this protein is highly glycosylated [22].
Two different extracts of PSK were also used: one rich in
sugars and other rich in proteins.
Cell lines and cell culture
The following tumour cell lines were studied: B16 murine
melanoma, B9 murine MCA-induced fibrosarcoma,
Ando-2 human melanoma, AGS human gastric cancer, A-
549 human lung cancer, Hela human cervical adenocarci-
noma and Jurkat T lymphoma leukemia. The NKL studied
was established from PBLs of a patient with LGL leukemia
[19]. All cell lines were obtained from the American Type
Culture Collection (Manassas, USA) except for the B9 cell
line, which was generated at our laboratory, and the
Ando-2 and NKL cell lines, kindly provided by P. Coulie
(Unite de Genetique Cellulaire, Louvain University, Brus-
sels, Belgium), F. X. Real (Instituto Municipal de Investi-
gaciones Medicas, Barcelona, Spain) and Dr. M. Lopet-
Botet (Universidad Pompeu-Fabra, Barcelona, Spain),
respectively.
Cell lines derived from solid tumours were grown at 37°C
in a humidified atmosphere of 5% CO2 in DMEM culture
medium (Gibco, Paisley UK) supplemented with 10%
heat-inactivated foetal bovine serum (Life Technologics,
Milan Italy), antibiotics and glutamine. Jurkat T cell leuke-
mia was cultured in RPMI 1640 with 10% heat-inacti-
vated fetal bovine serum. The NKL cell line was cultured
in RPMI 1640 with 10% heat-inactivated human AB
serum (Sigma Chemical, St Louis, MO; USA) and human
recombinant IL-2 (100 U/ml; purity > 97%, specific activ-
ity, 2 × 106 U/mg) (Roche, Nutley, NJ; USA).
In vitro cytotoxicity assays
The effect of PSK on tumour cell proliferation was
assessed by measuring BrdU incorporation with the BrdU
colorimetric ELISA Cell Proliferation Kit (Roche Diagnos-
tic). Cells were plated in 96-well microculture plates (5 ×BMC Cancer 2008, 8:78 http://www.biomedcentral.com/1471-2407/8/78
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103  cells/well). Every 48 h, the culture medium was
replaced and PSK was added. After 48–96 h, BrdU label-
ling reagent was added and cultured for a further 1–3 h.
Assays were also performed by counting viable cells using
Trypan Blue. Briefly, cancer cell lines were seeded into cul-
ture tissue-flask (1.5–2 × 105/culture tissue-flask) and
incubated for 24 h at 37°C in a humidified atmosphere of
5% CO2. Cells were then treated with 100 μg/ml of PSK in
the culture medium, which was replaced every 48 h. After
4–6 days, cells were collected by centrifugation and a
small sample of cell suspension was diluted in 0.4%
Trypan Blue, counting cells in a haemocytometer cham-
ber. Each cell sample was counted in this way at least three
times and each assay was repeated at least three times.
Lymphocyte and NKL proliferation assay
Human lymphocytes were isolated from venous blood by
the Ficoll-Hystopaque separation method. Proliferation
of PBLs was analyzed in vitro using 5-bromo-2'-deoxyuri-
dine (BrdU) labelling of DNA-synthesizing cells with the
above-mentioned kit. PBLs were seeded in 96-well micro-
culture plates at a cell density of 5 × 104 per well. Two dif-
ferent concentrations of PSK were used, 100 μg/ml and 50
μg/ml. Concanavalin A (5 μg/ml, Sigma) and IL-2 were
used as positive controls. PSK was also used in combina-
tion with IL-2 or Concanavalin A. After 48 h of culture in
presence or absence of PSK, BrdU labelling reagent (final
concentration 10 μM) was added and cells were cultured
for 24 h. Cells were then fixed for 30 min and incubated
with anti-BrdU for 1 h at 37°C. 100 μl of tetramethyl-ben-
zidine (TMB) was used as substrate. Optical densities were
determined at 370 nm by means of an ELISA microplate
reader (Biotek, Power-Wave XS). Controls were the cul-
ture medium, cells cultured only in medium and cells
incubated with anti-BrdU in absence of BrdU. All experi-
ments were repeated at least three times.
Cell cycle distribution analysis
Briefly, cells were plated in six-well plates (5 × 105 per
well) or in culture tissue-flask (15 × 105) and continu-
ously exposed for 4 days to 100 μg/ml of PSK. The DNA
synthesis rate was examined by BrdU incorporation
method using FITC BrdU Flow Kit (BD Pharmingen)
according to manufacturer's instructions. BrdU was then
detected by DNase cell treatment using FITC-conjugated
anti-BrdU antibody. Cells were washed with 1 ml 1 × BD
Perm/Wash Buffer, and 20 μl 7-amino-actinomycin D was
added. Analysis was performed with 50000 cells using
Cell Quest Software and FACScan flow cytometer (Becton-
Dickinson).
Annexin V binding assay to detect apoptotic cells
After treatment of cancer cells with PSK for four days, cells
were detached from the culture tissue-flask with PBS con-
taining 3 mM EDTA. These cells were then collected
together with floating cells, washed twice with cold PBS
and resuspended in binding buffer at a concentration of 1
× 106 cells per ml; 100 μl of solution was incubated for 30
min at 4°C with 5 μl of Annexin V-PE antibody (BD Bio-
sciences), and 5 μl of 7-amino-actynomycin D was then
added. Cells were incubated for 15 min in darkness, and
400 μl of staining buffer was added before flow cytometry
analysis. Apoptosis was analyzed by quadrant statistics as
follows: Annexin V- and 7-AAD-negative cells are alive;
Annexin V-positive and 7-AAD-negative cells are in early
stages of apoptosis; Annexin V-negative and 7-AAD-posit-
ice cells are dead but not by apoptosis; and Annexin V-
positive and 7-AAD-positive cells are in mid- or end-stage
apoptosis.
Assay for active caspase-3 expression
FITC conjugated monoclonal anti-active-caspase-3 anti-
body (BD Biosciences) was used to determine whether the
protease caspase-3 is involved in PSK-induced apoptosis.
After 4-day treatment with PSK, cancer cells were washed
twice with cold PBS and fixed and permeabilized in
Cytofix/Cytoperm buffer. Then, cells were incubated with
FITC-conjugated monoclonal rabbit anti-active human-
caspase-3 antibody for 30 min. Cells were washed twice
and 500 μl of 1 × Perm Wash Buffer was added before
analysis by flow cytometry.
Statistical analysis
Values are expressed as means ± SD. Student's t-test was
used for statistical comparisons, considering a signifi-
cance value of P < 0.05.
Results
PSK inhibits in vitro tumour cell proliferation
Tumour cell lines were cultured in 96-well plate for 48–72
h (2.5–5 × 103 cells) in medium alone (control) or with
PSK (100 μg/ml or 50 μg/ml) for 4–6 days. Cell prolifera-
tion was then measured by BrdU incorporation (absorb-
ance), which was significantly lower in PSK-treated versus
untreated tumour cells (Fig. 1). AGS and A549 cell lines
showed a strong decrease in absorbance after treatment
with 100 μg/ml PSK that was less marked after treatment
with 50 μg/ml of PSK. Inhibition of proliferation was
around 65% in melanoma cell lines B16 and Ando-2,
lower in Hela and Jurkat cell lines and lowest (20%) in B9
murine fibrosarcoma (Fig. 1). PSK-treated tumour cells
showed morphological changes (rounded and granulated
morphology, increased vacuolisation, cell shrinkage) and
a large number of the cells detached from culture flasks.
These assays were repeated in cell culture flasks (1.5–2.5 ×
105cells), and viable cells were counted in Haemacytome-
ter chamber using Trypan Blue. As shown in Table 1, there
was a significant decrease in the final number of viable
cells, with a proliferation inhibition of 22%–84% versusBMC Cancer 2008, 8:78 http://www.biomedcentral.com/1471-2407/8/78
Page 4 of 10
(page number not for citation purposes)
control cells. There was an excellent correlation between
the results obtained with the two assays (absorbance and
cell count). In Hela tumour cells, proliferation inhibition
was higher after treatment with 50 μg/ml versus 100 μg/
ml of PSK. In all other tumour cell lines, proliferation
inhibition was similar or higher at 100 μg/ml PSK.
PSK increases in vitro proliferation of IL-2-stimulated 
lymphocytes
A dose-response analysis was performed to determine the
in vitro effect of PSK on human PBLs. PBLs (5 × 104) were
plated in 96-well tissue plate for 48–72 h with eight seri-
ally diluted extractions ranging from 500 μg/ml (concen-
tration n°8) to 3.9 μg/ml (concentration n°1).
Concentration n°0 represents cells cultured in medium
alone. BrdU incorporation during DNA synthesis was
then measured by ELISA. Optical densities were very sim-
ilar between treated and untreated PBLs (data not shown).
However, simultaneous treatment of PBLs with IL-2 (100
U/ml) + PSK (100 μg/ml) produced a higher proliferation
rate (4.5-fold) versus PBLs treated with IL-2 alone (3-fold)
(Fig. 2). Untreated and Concanavalin A-treated PBLs
served as controls (Fig. 2).
Effect of different variants of PSK
Tumour cell proliferation inhibition was compared
among different PSK variants. Neuraminidase treatment
digests glicosylated proteins. A549 tumour cell line was
cultured in medium alone (control) or with PSK (100 μg/
ml) or neuraminidase-treated PSK (100 μg/ml) for 4–6
Effect of PSK on PBL proliferation Figure 2
Effect of PSK on PBL proliferation. PBLs were cultured 
with PSK or IL-2 or with PSK+IL-2. PBLs (50 × 104 cells) 
were seeded in quadruplicate in 96-well plates. The prolifera-
tion was determined by BrdU incorporation and absorbance 
measurement. PSK showed a synergistic effect with IL-2, 
increasing PBL proliferation. PSK alone did not induce PBLs 
proliferation. Each column represents the mean of five inde-
pendent experiments ± SD. *P < 0.001 versus control.

	
  
  









	









Table 1: Proliferation of tumour cell lines treated with PSK
Cell No. (× 104) % inhibition
Tumour cell line Initial Control PSK1* PSK2* PSK1 PSK2
B16 25 220 ± 5 100 ± 2 92 ± 2 62 65
AGS 14 40 ± 1 18 ± 1 21 ± 1 84 71
Hela 25 180 ± 5 108 ± 4 91 ± 4 46 57
A549 25 260 ± 5 72 ± 2 104 ± 3 80 56
Jurkat 80 325 ± 5 224 ± 3 208 ± 3 41 47
B9 20 90 ± 4 75 ± 3 72 ± 3 22 26
Ando-2 15 30 ± 1 20 ± 1 22 ± 1 67 54
*PSK1: 100 μg/ml; PSK2: 50 μg/ml. P < 0.001 versus control
Effect of PSK on tumour cell line proliferation Figure 1
Effect of PSK on tumour cell line proliferation. B16, 
A549, Hela, AGS, Jurkat, B9 and Ando-2 tumour cell lines 
were treated or not with 50 μg/ml or 100 μg/ml of PSK for 
72–96 h. Tumour cells (2.5 to 5 × 104) were plated in quad-
ruplicate in 96-well plates. The proliferation of tumour cells 
was determined by BrdU incorporation and absorbance 
measurement. All cell lines analysed showed inhibition of 
proliferation. Each column represents the mean of five inde-
pendent experiments ± SD. P < 0.001 versus control.
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days and then counted using trypan blue. No significant
differences in proliferation inhibition were found
between PSK and neuraminidase-treated PSK (Fig. 3a).
The same results were found for sugar-rich and protein-
rich PSK variants as for PSK (data not shown).
It was previously reported that PSK induces proliferation
and activation of NKL cells [16]. Treatment of NKL cells
with 100 μg/ml PSK or neuraminidase-treated PSK for 96
h induced a similar increase in their proliferation (Fig.
3b), which was slightly higher than that obtained after
culture of NKL with IL-2 alone (Fig. 3b). Induction of NKL
proliferation was slightly lower in sugar-rich and protein-
rich PSK variants; this difference was not significant (data
not shown)
Cell cycle phase distribution analysis of PSK-treated cells
Mechanisms of PSK cytotoxic activity were analysed by
flow cytometry in order to study the effect on cell cycle
phase distribution. Culture of AGS tumour cell line with
100 μg/ml of PSK produced total cell cycle arrest with cell
accumulation in G0/G1 phase and no cells in S phase (Fig.
4). Cell cycle phase distributions were: 32.2% G0/G1,
31.1% S and 16.2% G2/M in control AGS cells and 60.8%
G0/G1, 0% S and 14.1% G2/M in PSK-treated AGS cells.
Similar results were found in Ando-2, A549 and B16
tumour cell lines (Table 2). Results in B9 fibrosarcoma
showed a slowing rather than an arrest of the cell cycle
(Fig.4), with a partial accumulation in G0/G1  phase
(49.15% untreated cells and 63.17% PSK-treated cells) at
the expense of a decrease in S phase (20.54% vs. 15.14%)
and G2/M phase (12.6% vs. 6.96%). Similar results were
found in Hela and Jurkat tumour cells (Table 2). These
results indicate that PSK produces arrest or slowing of the
cell cycle according to the tumour cell histology.
Analysis of apoptosis in tumour cells treated with PSK
Cancer cell lines were treated with 100 μg/ml PSK for 4
days to examine the capacity of PSK to induce apoptosis.
Untreated or PSK-treated cancer cells were incubated with
Annexin V-PE in a buffer containing 7-amino-actinomy-
cin (7-AAD) and analyzed by flow cytometry. Figure 5
depicts representative results for AGS and B9 tumour cells.
PSK increased apoptosis from 4.32% (untreated cells) to
37.52% in AGS cells but not in B9 tumour cells (untreated
cells, 11.37% vs. PSK-treated cells, 12.11%). Table 3
depicts the results for other tumour cell lines, showing
that PSK induces apoptosis in A549, B16 and Ando-2
tumour cells.
Table 2: Effect of PSK on cell cycle distribution of tumor cell 
lines.
Tumour cell line Cell cycle distribution (%)
SUB-G1 G2 S G1
AGS control 5.12 16.20 31.10 32.20
AGS PSK 12.23 14.10 0 60.80
Ando-2 6.35 18.12 32.25 33.46
Ando-2 PSK 12.40 16.30 4.35 60.10
A549 control 7.25 15.53 31.15 30.67
A549 PSK 11.95 13.13 5.20 49.45
B16 control 8.35 12.25 30.23 31.45
B16 PSK 14.35 8.35 5.45 55.67
Jurkat control 8.23 18.60 32.35 25.50
Jurkat PSK 11.30 18.35 15.25 45.35
HELA control 5.58 16.35 21.12 44.67
HELA PSK 10.57 9.56 14.78 51.56
B9 5.20 12.60 20.54 49.15
B9 PSK 6.56 6.96 15.14 63.17
Results are for one typical experiment out of three performed.
In vitro activity of neuraminidase treated-PSK Figure 3
In vitro activity of neuraminidase treated-PSK. a) 
A549 tumour cell line was cultured with neuraminidase-
treated PSK or PSK. A549 tumour cells (20 × 104) were 
seeded in culture flask and treated with PSK for 96 h, esti-
mating cell viability by means of Trypan blue exclusion. Both 
agents produced a similar inhibition ofproliferation. b) NKL 
cell line was cultured with PSK or neuraminidase treated-PSK 
and proliferation was determined by BrdU incorporation and 
absorbance measurement. Both agents induced a similar 
increase of proliferation. Each column represents the mean 
of five independent experiments ± SD. *P < 0.001 versus 
control.
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Expression of active human caspase-3
Caspases are the main enzymes involved in the apoptotic
pathway and the participation of active caspase-3 in PSK-
induced apoptosis was evaluated. Tumour cells were
treated with PSK (100 μg/ml) for 4 days, then permeabi-
lized, fixed and stained for active human caspase-3 and
analyzed by flow cytometry. In the AGS cell line,
untreated cells were negative for presence of active-cas-
pase-3, whereas around 36% of PSK-treated cells showed
detectable active caspase-3 (Fig. 6). However, in tumour
cell lines in which PSK did not produce apoptosis, e.g., B9
tumour cells, no caspase-3 expression was detected after
PSK treatment (Fig. 6). Table 4 depicts the results
obtained with the other tumour cell lines analysed.
Discussion
Several clinical assays have reported the anti-tumour
properties of PSK and its synergestic effect in combined
therapies [9,24,25]. Our group previously reported the
immunomodulatory activity of PSK on NK cells, produc-
ing  in vitro proliferation and activation of NKL cells
[16,20,21]. In the present study, we have identified a new
cytotoxic anti-tumour activity of PSK. This activity varied
according to the histological origin of the tumour cell
lines under study, with inhibition rates ranging from 84%
to 22% (Table 1). The highest profileration inhibition
rates were found in AGS (84%) and A549 (80%) cell lines
(gastric and lung cancer, respectively). PSK was previously
reported to be effective in adjuvant immunotherapy for
patients after curative resection of gastric cancer [25], and
this effect was attributed to its immunomodulatory activ-
ity on NK cells [26]. Our group previously reported that
Cell cycle analysis of cells treated with PSK Figure 4
Cell cycle analysis of cells treated with PSK. Tumour cell lines were treated with PSK for 96 h. Cell cycle distribution 
was determined by flow cytometry using BrdU incorporation and 7-AAD. Data indicate the percentage of cells in each phase of 
cell cycle. Results are representative of three independent experiments.
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PSK mediates induction of the NKL cell proliferation and
activation. The present results suggest that PSK may also
exert a direct antitumour cytotoxic activity. Inhibition was
around 65% in melanoma cell lines Ando-2 (human) and
B16 (mice) and was lowest (22%) in the B9 murine fibro-
sarcoma cell line. Deglycosylation of PSK by neuramini-
dase treatment did not modify its cytotoxic effect on
tumour cell lines. The sugar-rich and protein-rich PSK var-
iants showed identical results to those of PSK in their inhi-
bition of proliferation of tumour cell lines in vitro. These
results indicate that the cytotoxic properties are in a com-
pound that is present in all three variants studied and does
not vary among them.
Interestingly, PSK had the opposite effect on lymphocytes.
Thus, PSK, in synergy with IL-2, induced proliferation of
Table 3: Apoptosis induction in cancer cell lines after treatment 
with PSK for 4 days.
Tumour cell line Apoptosis (%)
Control PSK 100 μg/ml
AGS 4.32% 37.52%
A549 10.40% 35.50%
B16 8.90% 25.40%
Ando-2 7.98% 18.35%
JURKAT 6.10% 10.71%
HELA 9.35% 14.30%
B9 11.37% 12.11%
This assay was repeated at least three times, producing similar results.
Apoptosis analysis of cells treated with PSK Figure 5
Apoptosis analysis of cells treated with PSK. AGS cell line was untreated or treated with 50 μg/ml of PSK for 96 h. Cells 
were double-stained with annexin V and 7AAD and analyzed by flow cytometry. PSK produced apoptosis in AGS tumour cell 
line. B9 tumour cell line was also cultured with PSK but apoptosis was not detected in this tumour cell line. All experiments 
were performed at least three times and gave similar results.
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PBLs. PSK also induced proliferation and activation of
NKL cells, producing an effect similar to that of IL-2.
Hence, PSK has a cytotoxic effect on tumour cells and a
mitotic effect on lymphocytes and NK cells.
The cell cycle was arrested or slowed by PSK according to
the histological origin of the tumour cells. PSK is known
to increase docetaxel-induced apoptosis of NOR-P human
pancreatic cancer cells [27] and of Namalwa Burkitt lym-
phoma cells [28]. PSK induced apoptosis in the AGS cell
line but not in all tumour cell lines analysed and induced
caspase-3 expression in some tumour cell lines but not all.
These results indicate that PSK may induce cytotoxic activ-
ity by different molecular mechanisms according to the
histology of tumour.
Table 4: Expression of caspase-3 in cancer cell lines after 
treatment with PSK for 4 days.
Tumour cell line Expression (%)
Control PSK100 μg/ml
AGS 5.37% 36.13%
A549 4.20% 31.14%
B16 6.80% 23.35%
Ando-2 5.40% 15.55%
JURKAT 5.35% 6.45%
HELA 6.50% 6.15%
B9 3.93% 3.74%
This assay was repeated at least three times, producing similar results
Caspase-3 expression in tumour cell lines treatedwith PSK Figure 6
Caspase-3 expression in tumour cell lines treatedwith PSK. AGS and B9 tumour cell lines were treated with 50 μg/ml 
of PSK and expression was analysed by flow cytometry using FITC conjugated monoclonal anti-active-caspase-3 antibody. Data 
indicate the percentage of cells positive for presence of active-caspase-3. PSK produced increased caspase-3 expression in AGS 
but not in B9 tumour cell lines. Results are representative of three experiments.
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The molecular mechanisms implicated in PSK-induced
proliferation and activation of NKL cells have been widely
described, showing that PSK and IL-2 bind to different
receptors on NKL cells and induce different signal trans-
duction pathways [20-22]. The present results indicate
that the anti-tumour properties of PSK observed in clinical
trials might be due to a dual biological activity: 1) a direct
cytotoxic activity on tumour cells and 2) an immunomod-
ulatory activity largely produced by NK cell activation. A
similar dual activity has also been described in a Calendula
extract, LACE, which produces an in vitro cytotoxic activity
and  in  vivo immunomodulatory effect on tumour cell
lines, including human and mouse melanioma cells,
increasing the number and activation of CD4+, CD19+
and NKT cells [29]. PSK suppressed in vivo metastases in
spontaneous metastasis assays of mouse fibrosarcoma,
melanoma, rat hepatoma AH60C and mouse colon can-
cer 26 [17,30,31]via  NK cell activation. Based on the
present findings, it can be hypothesised that this anti-met-
astatic capacity may also derive from the cytotoxic compo-
nent of PSK.
Research into the biological mechanisms underlying the
anti-tumour effect of PSK is ongoing. We can now add a
direct cytotoxic effect on tumour cells to the previously
described immunomodulatory effect of this polysaccha-
ride. Greater knowledge of the molecular mechanisms
implicated in PSK anti-tumour activity may improve can-
cer immunotherapy, leading to the application of new
anti-tumour protocols.
Conclusion
PSK shows in vitro growth inhibition of various tumour
cell lines, producing cell cycle arrest/slowing, apoptosis
and induction of caspase-3 expression. In combination
with IL-2, PSK induces proliferation of PBLs. The biologi-
cal activity of PSK appears to include both an immu-
nomodulatory effect on NK cells and a cytotoxic effect on
tumour cells
Abbreviations
PBLs: Peripheral Blood Lymphocytes; LACE: laser-acti-
vated calendula extract; 7-AAD: 7-amino-actinomicin D;
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A; LAK: lymphocyte-activated killer; NK: Natural killer;
TMB: tetramethyl-benzidine.
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